GAS5 and metabolic dysfunction-associated steatotic liver disease: Although GAS5 was upregulated in tissue and plasma as liver fibrosis progressed, its expression in plasma was significantly downregulated in patients with NAFLD who had developed cirrhosis (F = 3: 15.0 (12.8–22.0); F = 8.1 (4.0–10.1); P = 0.026, Figure 4).